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Abstract 
Background: Previous studies have shown that angiopoietin‑like protein 8 (ANGPTL8), also called as betatrophin, 
acts together with ANGPTL3 to regulate lipid metabolism, glucose metabolism, and energy homeostasis. Moreover, 
ANGPTL8 promotes proliferation of pancreatic β‑cells and induces insulin secretion. However, there are no previous 
longitudinal studies in humans.
Methods: We analyzed the age‑ and sex‑matched data of 240 normal weight and overweight Korean children from 
the Korean Metabolic disorders and Obesity Study in Elementary School children (K‑MOSES), a prospective observa‑
tional cohort study.
Results: At baseline, ANGPTL8 concentrations were positively associated with triglycerides (TG) (r = 0.168, P = 0.010), 
whereas ANGPTL3 levels were associated with fasting insulin (r = 0.248, P < 0.001) and the homeostasis model 
assessment of insulin resistance (HOMA‑IR) (r = 0.197, P = 0.002). Although both ANGPTL8 and ANGPTL3 levels did 
not differ between children with normal weight and children with overweight, ANGPTL8 levels were increased in 
males compared to females (341.2 [267.4–436.5] vs. 270.2 [213.9–378.8] pg/ml, P = 0.001). In particular, there was no 
significant inter‑relationship between circulating ANGPTL8 and ANGPTL3 concentrations in Korean boys and girls 
(r = −0.073, P = 0.265). Multivariate analysis showed that baseline ANGPTL8 concentrations were independently 
associated with future changes of serum TG levels in Korean children after adjusting for confounding factors after a 
3 year follow‑up period (r = −0.165, P = 0.016).
Conclusions: This longitudinal study demonstrated for the first time that baseline ANGPTL8 levels were associated 
with baseline and future changes in TG levels in Korean children.
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Background
Recently, angiopoietin-like protein 8 (ANGPTL8) was 
identified as a novel hormone that induces a remark-
able dose-dependent increase in pancreatic β-cell pro-
liferation [1]. Also known as betatrophin, lipasin, and 
refeeding-induced fat and liver protein (RIFL), other 
researchers have also reported the identification and 
function of ANGPTL8 [2]. ANGPTL8, which is expressed 
in liver and adipose tissue, is upregulated by feeding and 
suppressed by fasting in mice and humans [3, 4]. Also, 
in one study, adenovirus-induced overexpression of 
ANGPTL8 resulted in increased serum triglyceride (TG) 
levels in mice [3]. Ren et al. reported the induction of the 
ANGPTL8 gene during adipogenesis and knockdown 
of the ANGPTL8 gene led to reduced adipogenesis and 
reduced TG storage [4]. In addition, there is evidence 
that ob/ob mice have a significant increase in ANGPTL8 
transcript levels in their adipose tissue [4]. Impor-
tantly, a recent cross-sectional study demonstrated that 
ANGPTL8 concentrations were increased in the plasma 
of patients with type 1 diabetes compared to controls [5]. 
Furthermore, Hu et  al. reported that serum ANGPTL8 
levels were significantly higher in patients with type 2 
diabetes than in healthy control subjects [6]. However, 
Gusarova et al. showed that overexpression of ANGPTL8 
in livers of mice did not change β-cell expansion or glu-
cose metabolism, although it doubled plasma TG levels 
[7]. Therefore, further research is needed for evaluating 
the role of ANGPTL8 in human metabolic disorders.
ANGPTL3 is an important regulator of lipoprotein 
metabolism, and deletion or overexpression of ANGPTL8 
and ANGPTL3 have similar effects on lipid profiles in 
mice [8]. Quagliarini et al. demonstrated that ANGPTL8 
interacts with ANGPTL3 and facilitates its cleavage [9]; 
ANGPTL3 needs to be cleaved to release the functional 
N-termini, which inhibits lipoprotein lipase (LPL) and 
results in reduced TG clearance and a phenotype with 
greater TG stores [10]. Although plasma TG levels did 
not change in mice overexpressing ANGPTL3 alone, co-
overexpression of ANGPTL3 and ANGPTL8 resulted in 
hypertriglyceridemia. Furthermore, overexpression of 
ANGPTL8 in ANGPTL3-knockout mice failed to pro-
mote hypertriglyceridemia [9]. These results indicate 
that there is a close interaction between ANGPTL3 and 
ANGPTL8 in mice, but there is no previous report about 
their inter-relationship in humans. Furthermore, betat-
rophin has been mainly investigated in older adults, and 
there are no studies on the children. To the best of our 
knowledge, there is no longitudinal study that examines 
the association between ANGPTLs and changes in meta-
bolic profiles. In the present study, we analyzed data from 
a prospective observational study to examine the impact 
of ANGPTL3 and ANGPTL8 in relation to baseline and 
follow-up anthropometric and metabolic profiles in 
Korean boys and girls.
Methods
Study subjects
Study subjects were selected from the Korean Meta-
bolic disorders and Obesity Study in Elementary School 
children (K-MOSES), an observational cohort study to 
examine children annually since 2006 at eight elemen-
tary schools in Seoul, South Korea. The main aim of 
K-MOSES is to comprehensively and prospectively assess 
obesity-related metabolic risk factors and to evaluate 
clinical outcomes in Korean children. The details of the 
cohort were described previously [11, 12]. We recruited 
457 children, aged 9 year at baseline, who participated in 
a school-based health examination in 2007 and reexam-
ined at a 3  year follow-up assessment in 2010. Subjects 
with insufficient anthropometric and biochemical labo-
ratory data (n  =  137) were excluded, so data from 320 
subjects (164 males and 156 females) were analyzed in 
the present study. A total of 52 (14 males and 38 females) 
out of 320 subjects (16.3 %) were defined as overweight. 
As we conducted a case–control analysis matched for 
age and sex, 28 overweight subjects (14 males and 14 
females) were randomly selected as cases and 212 normal 
weight subjects were enrolled as controls (106 males and 
106 females). None of the children had a history of car-
diovascular disease, diabetes, hypertension, or endocrine 
disorders, and they were nonsmokers. Written informed 
consent was obtained from their parents and the Korea 
University Institutional Review Board approved this 
study protocol in accordance with the Declaration of 
Helsinki of the World Medical Association (approval No. 
KUGH 11004-001).
Anthropometric and laboratory measurements
During both visits anthropometric measurements were 
obtained from all children in light clothing without 
shoes. Height and weight were measured by an auto-
matic height-weight scale, to the nearest 0.5  cm and 
0.5 kg, respectively; BMI was computed as weight (kilo-
grams)/height (meters). Waist circumference was meas-
ured at the midpoint between the lower border of the rib 
cage and the top of the lateral border of the iliac crest. 
We defined normal weight (girl’s BMI  <  19.88, boy’s 
BMI < 20.76) among children on the basis of the Korean 
Pediatric Society 2005 guidelines, which defines as hav-
ing a BMI below the 85th percentile for age and sex [13]. 
Blood pressure was measured with a standard brachial 
cuff technique. Self-reported information on pubertal 
development was collected, using a Tanner drawing of 
the five stages of pubertal development, which involved 
the development of genitalia and pubic hair [14]. All 
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blood samples were obtained the morning after an 8  h 
overnight fast, and were immediately stored at −80  °C 
for subsequent analysis. Serum total cholesterol, TG, 
and high-density lipoprotein cholesterol (HDL-C) lev-
els were determined enzymatically using a model 747 
chemistry analyzer (Hitachi, Tokyo, Japan). AST and ALT 
levels were determined enzymatically with the aid of an 
auto-analyzer (TBA-200FR; Toshiba, Tokyo, Japan). The 
glucose oxidase method was used to measure plasma 
glucose levels. The homeostasis model assessment of 
insulin resistance (HOMA-IR) was calculated as [fasting 
insulin (in microunits per milliliter) × fasting glucose (in 
mmol per liter)]/22.5. Serum ANGPTL3 concentrations 
were measured with an enzyme-linked immunosorbent 
assay (R&D systems, Minneapolis, MN, USA), and the 
intra- and inter-assay CVs were 2.7–4.1 % and 6.7–8.5 %, 
respectively. Serum ANGPTL8 concentrations were 
measured with an enzyme-linked immunosorbent assay 
(EIAAB, Wuhan, China) and the intra- and inter-assay 
CVs were less than 4.8 and 7.2 %, respectively.
Statistical analysis
Continuous variables with normal distributions are 
expressed as the mean ±  SD, whereas continuous vari-
ables with skewed distributions are expressed as the 
median and interquartile range. Baseline demographic 
and biochemical characteristics of the study population 
by sex were compared using an independent t test or the 
Mann–Whitney U test for continuous variables. Because 
serum levels of ANGPTL3 and ANGPTL8 were not nor-
mally distributed, log transformed values were used for 
the analysis. To evaluate the associations between hepa-
tokines and anthropometric and metabolic variables at 
baseline, Pearson’s correlations were used. Unadjusted 
Pearson’s correlations and Pearson’s partial correlations 
adjusted for confounding factors were used to evalu-
ate the association between ANGPTLs and changes in 
metabolic variables at the 3  year follow up. All statisti-
cal analyses were performed using SPSS version 20.0 
for Windows (SPSS Inc., Chicago, IL, USA). A P value 
of <0.05 was considered statistically significant.
Results
Characteristics of study subjects
Anthropometric and metabolic characteristics of the 
study participants at baseline and 3  year later are pre-
sented in Table 1. At baseline, girls were taller and heav-
ier than boys, and BMI and waist circumference were 
also greater in girls. However, blood pressure and labora-
tory measurements were similar except for fasting insu-
lin levels; girls had significantly higher insulin levels than 
boys. With that said, HOMA-IR and HOMA-β values 
were not different between boys and girls. In particular, 
ANGPTL8 concentrations were significantly greater in 
boys compared to girls, whereas ANGPTL3 levels were 
not different (Fig. 1a). On the other hand, we did find any 
significant differences in either ANGPTL8 or ANGPTL3 
levels between children with normal weight and over-
weight children (Fig. 1b).
Correlation analysis between ANGPTLs and clinical 
variables at baseline
Table  2 shows Pearson’s correlation analysis between 
log-transformed ANGPTL concentrations and clinical 
variables at baseline. ANGPTL3 levels were positively 
correlated with fasting insulin (r = 0.248, P < 0.001) and 
HOMA-IR (r = 0.197, P = 0.002) values as well as ALT 
levels (r =  0.131, P =  0.042). However, anthropometric 
measurements and laboratory values including glucose 
and lipid profiles were not correlated with ANGPTL3 
concentrations. In contrast, ANGPTL8 concentrations 
showed a positive relationship with triglyceride levels 
(r =  0.168, P =  0.010). However, other anthropometric 
and laboratory measurements were not correlated with 
ANGPTL8 levels. In particular, ANGPTL8 levels were 
not associated with HOMA-β (r  =  0.006, P  =  0.927) 
values, which reflect insulin secretory capacity. Interest-
ingly, there was no significant inter-relationship between 
circulating ANGPTL8 and ANGPTL3 concentrations in 
Korean children (r = −0.073, P = 0.265).
Multivariate analysis for the associations between baseline 
ANGPTLs and changes in clinical variables after a 3 year 
follow‑up period
Next, we analyzed the association between baseline 
ANGPTL concentrations and changes in anthropometric 
and laboratory measurements at the end of the 3 year fol-
low-up period (Table 3). In an unadjusted model, baseline 
ANGPTL8 concentrations were significantly associated 
with future changes in triglyceride levels (r  =  −0.166, 
P  =  0.011), although other laboratory and anthropo-
metric values were not correlated with ANGPTL8 lev-
els. This relationship persisted after adjustment for 
sex and Tanner stage (r = −0.191, P =  0.005). Further-
more, the statistical significance was maintained after 
further adjustment for BMI, SBP, and FPG (r = −0.165, 
P = 0.016). However, ANGPTL3 concentrations were not 
associated with any changes in clinical variables in both 
the unadjusted and adjusted models.
Discussion
In the present study, we found that baseline ANGPTL8 
levels were associated with baseline and future changes 
in TG levels in Korean children. However, there was 
no significant inter-relationship between circulating 
ANGPTL8 and ANGPTL3 concentrations.
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Angiopoietin-like proteins (ANGPTLs) are a fam-
ily of proteins structurally similar to the angiopoietins 
and have important roles in lipid and glucose metabo-
lism, inflammation, atherosclerosis, and hematopoie-
sis [8, 15, 16]. Eight members have been identified so 
far and denominated as ANGPTLs 1–8 [8]. Among 
ANGPTLs, ANGPTL2 can be considered a key media-
tor that links obesity and atherosclerosis [8, 16]. Particu-
larly ANGPTL3, ANGPTL8 and ANGPTL4 studied for 
a major role in TG regulator and in insulin mediator [8, 
17].
ANGPTL8 has been suggested as a potential target for 
β-cell regenerative therapy in diabetes. However, contra-
dictory results of ANGPTL8 in glucose metabolism have 
been reported in patients with type 2 diabetes. Some 
studies found that serum ANGPTL8 levels were elevated 
in patients with type 2 diabetes compared to subjects 
with nondiabetic subjects [6, 18–20]. Furthermore, Chen 
et al. observed that ANGPTL8 levels were positively cor-
related with insulin resistance indexes including HOMA-
IR [18]. Hu et  al. showed that age, 2  h post-OGTT 
glucose and postprandial serum insulin were independ-
ent factors that were associated with serum ANGPTL8 
levels. Ebert et al. demonstrated that treatment of 3T3-L1 
adipocytes with insulin induced ANGPTL8 expression 
in a dose-dependent manner [19]. Gao et  al. reported 
that ANGPTL8 are increased in newly diagnosed T2DM 
patients and decreased in patients with comparatively 
better islet beta cell function [21]. However, other stud-
ies reported decreased levels of betatrophin in T2DM 
through insulin resistance [22, 23]. Gokulakrishnan et al. 
reported that ANGPTL8/betatrophin levels are lower in 
youth-onset type 2 diabetes mellitus [22]. By contrast, 
Fenzl et  al. reported that ANGPTL8 levels are similar 
when comparing lean and morbidly obese patients or 
when comparing non-diabetic and type 2 diabetic par-
ticipants [24]. Although the exact reason for this dis-
crepancy has not been clearly defined, a recent study 
suggested that circulating ANGPTL8 concentrations 
do not mirror insulin action in either the liver or adi-
pose tissue [17]. In the present study, we did not find a 
significant relationship between baseline ANGPTL8 
levels and future changes in fasting glucose and obesity 
parameters such as BMI and waist circumference. Fur-
thermore, ANGPTL8 concentrations were not associated 
with HOMA-β or HOMA-IR values and did not differ 
between normal weight and overweight children. Most 
previous ANGPTL human studies have been investigated 
in older adults, there is limited data of ANGPTL levels 
in children. Studies in younger age participants may be 
valuable, because they may be less influenced by various 
comorbid status and lifestyle factors.
Previous studies have shown that ANGPTL8 regu-
lates lipid metabolism. Fenzl et al. found that ANGPTL8 
concentrations are correlated with atherogenic lipid 
profiles [24]. Gusarova et  al. reported that plasma TG 
Table 1 Anthropometric and metabolic characteristics of study participants at baseline and after 3 year
All values are mean ± standard deviation or median and interquartile range
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, TC total cholesterol, TG 
triglycerides, HDL-C high-density lipoprotein cholesterol, AST aspartate aminotransferase, ALT alanine aminotransferase
a  Independent t-test or b the Mann–Whitney U
Baseline 3 year later
Male (n = 120) Female (n = 120) P Male (n = 120) Female (n = 120) P
Height (cm) 130.6 (128.8−131.9) 136.0 (133.8−138.6) <0.001b 150.8 ± 7.0 153.1 ± 5.3 0.004a
Weight (kg) 28.5 (26.1−31.3) 31.9 (28.2−36.5) <0.001b 43.4 (36.6−51.2) 43.4 (40.8−49.3) 0.213b
BMI (kg/m2) 16.9 (15.4−18.4) 17.5 (16.2−19.2) 0.047b 19.2 (17.4−22.0) 19.6 (17.9−21.9) 0.298b
WC (cm) 57.0 (53.8−61.0) 59.5 (56.0−64.0) 0.004b 65.0 (59.6−74.5) 66.0 (61.7−72.9) 0.625b
SBP (mmHg) 105.5 (98.0−110.0) 105.0 (100.0−112.0) 0.676b 110.0 (110.0−120.0) 115.0 (110.0−120.0) 0.032b
DBP (mmHg) 66.0 (60.0−70.0) 65.5 (60.0−72.0) 0.544b 70.0 (65.0−80.0) 75.0 (70.0−80.0) 0.022b
FPG (mmol/L) 4.6 (4.3−4.9) 4.7 (4.5−5.0) 0.376b 4.1 ± 0.4 4.1 ± 0.3 0.584a
Insulin (μIU/ml) 6.6 (5.0−8.0) 7.4 (5.7−9.1) 0.026b – – –
HOMA‑IR 1.4 (1.0−1.7) 1.5 (1.1−2.0) 0.110b – – –
HOMA‑β 110.3 (80.6−158.4) 115.3 (79.9−165.2) 0.893b – – –
TC (mmol/L) 4.3 (3.9−4.7) 4.3 (3.8−4.7) 0.527b 3.9 (3.5−4.4) 4.0 (3.7−4.4) 0114b
TG (mmol/L) 0.7 (0.5−1.0) 0.7 (0.5−1.0) 0.324b 0.8 (0.6−1.1) 0.9 (0.8−1.2) <0.001b
HDL‑C (mmol/L) 1.5 (1.2−1.7) 1.5 (1.3−1.6) 0.942b 1.4 (1.2−1.7) 1.4 (1.2−1.5) 0.133b
AST (IU/L) 26.0 (23.0−30.0) 26.0 (22.0−29.0) 0.326b 25.0 (23.0−29.) 21.0 (18.0−24.0) <0.001b
ALT (IU/L) 22.0 (20.0−25.0) 23.0 (21.0−26.0) 0.406b 14.0 (12.0−18.0) 11.0 (10.0−13.0) <0.001b
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levels have been shown to be reduced in response to 
ANGPTL8 deletion and greater in response to overex-
pression of ANGPTL8 [7]. Collectively, these results 
suggest that inhibition of ANGPTL8 could be a thera-
peutic strategy to ameliorate hypertriglyceridemia. Wang 
et  al. also reported that mice lacking ANGPTL8 exhib-
ited disrupted TG metabolism [25]. However, there has 
been controversy in terms of if and how ANGPTL8 
regulates lipid metabolism. Ren et al. demonstrated that 
ANGPTL8 is lipogenic [4]. Quagliarini et al. reported that 
Fig. 1 Comparison of circulating ANGPTL concentrations under different baseline conditions. a Male (n = 120) vs. female (n = 120); ANGPTL3 
(271.7 [238.9–323.2] vs. 285.2 [249.8–338.8] ng/ml, P = 0.117), and ANGPTL8 (341.2 [267.4–436.5] vs. 270.2 [213.9–378.8] pg/ml, P = 0.001). b Normal 
weight (n = 212) vs. overweight (n = 28); ANGPTL3 (280.0 [242.4–332.5] vs. 292.4 [252.7–329.5] ng/ml, P = 0.500), and ANGPTL8 (298.0 [228.8–408.7] 
vs. 355.4 [265.3–473.1] pg/ml, P = 0.283, *P < 0.05
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ANGPTL8 increases lipolysis and regulates postprandial 
TG and fatty acid metabolism, owing to the assistance in 
activation of ANGPTL3 [9]. On the other hand, Zhang 
et  al. showed that ANGPTL8 reduces TG clearance via 
LPL inhibition, thereby increasing the serum TG con-
tent [3]. In the present study, ANGPTL8 concentration 
were positively associated with TG levels in Korea chil-
dren at baseline. Our results are consistent with previous 
cross-sectional data that suggest a relationship between 
ANGPTL8 and lipid profile, especially circulating TG 
concentrations [21]. Furthermore, we observed a signifi-
cant association between baseline ANGPTL8 concentra-
tions and future changes in serum TG levels in humans 
in the longitudinal study. Further studies are needed to 
explore the biological mechanisms involving ANGPTL8 
in the pathogenesis of hypertriglyceridemia.
ANGPTL3 mRNA is expressed exclusively in the liv-
ers of mice and humans, and plays several roles in lipid 
transport and metabolism. In a mouse study, adenovirus-
mediated overexpression of ANGPTL3 or treatment of 
recombinant ANGPTL3 significantly elevated plasma 
levels of nonesterified fatty acids (NEFA), total choles-
terol and TG [26]. Also, ANGPTL3 increased very low 
density lipoprotein (VLDL)-TG levels by inhibiting LPL 
activity [27]. In addition, ANGPTL3 binds to adipo-
cytes and causes the release of NEFA through activating 
lipolysis [28]. Moreover, ANGPTL3 acts as an inhibitor 
of endothelial lipase (EL) and hence decreases plasma 
HDL cholesterol levels [29]. Furthermore, ANGPTL3 
deficiency is associated with increased insulin sensitivity 
and decreased serum free fatty acids, suggesting a major 
role of ANGPTL3 in modulating both lipid and glucose 
metabolism [30]. Yilmaz et  al. reported that ANGPTL3 
concentrations were significantly higher in patients with 
Table 2 Pearson’s correlations between  log-transformed 
ANGPTLs and  anthropometric and  metabolic variables 
at baseline
BMI body mass index, WC waist circumference, SBP systolic blood pressure, 
DBP diastolic blood pressure, FPG fasting plasma glucose, TC total cholesterol, 
TG triglycerides, HDL-C high-density lipoprotein cholesterol, AST aspartate 
aminotransferase, ALT alanine aminotransferase, HOMA-IR homeostasis model 
assessment of insulin resistance
* P < 0.05
ANGPTL3 ANGPTL8
r P r P
Height (cm) −0.059 0.366 −0.111 0.089
Weight (kg) −0.038 0.562 −0.068 0.302
BMI (kg/m2) −0.016 0.804 −0.017 0.789
WC (cm) −0.002 0.978 −0.071 0.278
SBP (mmHg) 0.023 0.723 0.111 0.090
DBP (mmHg) 0.094 0.145 0.009 0.886
FPG (mmol/L) −0.112 0.084 0.093 0.153
TC (mmol/L) −0.045 0.490 0.035 0.595
TG (mmol/L) 0.042 0.521 0.168 0.010*
HDL‑C (mmol/L) −0.016 0.804 −0.053 0.414
AST (IU/L) 0.108 0.094 0.091 0.162
ALT (IU/L) 0.131 0.042* −0.022 0.732
Insulin (μIU/ml) 0.248 <0.001* −0.010 0.881
HOMA‑IR 0.197 0.002* 0.018 0.784
HOMA‑β 0.055 0.401 0.006 0.927
Table 3 Pearson’s correlations for the association between baseline ANGPTL concentrations and changes (Δ) in anthro-
pometric and metabolic variables after a 3 year follow-up period
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, TC total cholesterol, TG 
triglycerides, HDL-C high-density lipoprotein cholesterol
* P < 0.05
Unadjusted model Adjusted for sex, tanner stage,
BMI, SBP, and FPG
ANGPTL3 ANGPTL8 ANGPTL3 ANGPTL8
r P r P r P r P
ΔHeight 0.124 0.055 0.045 0.488 0.153 0.025* −0.028 0.688
ΔWeight 0.104 0.110 0.032 0.625 0.104 0.128 −0.013 0.850
ΔBMI −0.007 0.915 0.081 0.212 −0.020 0.768 0.072 0.292
ΔWC −0.010 0.878 −0.009 0.893 −0.042 0.542 0.015 0.827
ΔSBP 0.002 0.973 −0.093 0.157 0.016 0.816 −0.032 0.640
ΔDBP −0.034 0.604 −0.074 0.258 −0.040 0.564 −0.033 0.631
ΔFPG 0.125 0.053 −0.075 0.251 0.020 0.771 −0.035 0.606
ΔTC 0.083 0.203 −0.039 0.551 0.071 0.304 0.028 0.685
ΔTG 0.098 0.131 −0.166 0.011* 0.066 0.335 −0.165 0.016*
ΔHDL‑C −0.101 0.119 0.011 0.867 −0.102 0.137 0.015 0.823
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nonalcoholic steatohepatitis (NASH) and positively asso-
ciated with HOMA-IR [31]. In a cross-sectional study 
including 1770 Caucasian subjects, plasma ANGPTL3 
and ANGPTL4 concentrations showed different relation-
ships with plasma lipids [32]; ANGPTL3 was positively 
associated with LDL cholesterol and HDL cholesterol and 
not with metabolic syndrome traits including TGs. Using 
comparative analysis of genome-wide association studies, 
Angelakopoulou et al. demonstrated that a single nucleo-
tide polymorphism of ANGPTL3 (rs12042319) was asso-
ciated with coronary heart disease risk (OR = 1.11; 95 % 
CI = 1.03 ~ 1.19), total cholesterol, LDL-cholesterol, TG, 
and interleukin-6 [33]. In this study, we observed that 
ANGPTL3 concentrations were significantly associated 
with fasting insulin concentrations and HOMA-IR lev-
els, although an association with lipid profiles was not 
found. Previously, Robciuc et al. reported that ANGPTL3 
deficiency resulted in increased insulin sensitivity, which 
is associated with increased lipoprotein lipase activity 
and low circulating free fatty acids [30] and Wang et al. 
showed that Angptl3−/− mice increased insulin sen-
sitivity compared with wild-type animals by euglyce-
mic–hyperinsulinemic clamp studies [34]. In addition, 
baseline ANGPTL3 levels were not related to changes 
of anthropometric and biochemical variables after the 
3  year follow-up period in this study. In particular, 
there was no significant relationship between circulat-
ing ANGPTL8 and ANGPTL3 concentrations in Korean 
children (r = −0.073, P = 0.265).
Limitations
First, the number of subjects might not have been suf-
ficient to detect subtle changes of anthropometric and 
metabolic profiles in children. Second, the observational 
nature of our study did not allow direct proof of causal-
ity. Third, although the Tanner stage is accepted as the 
gold standard, we used self-reported Tanner staging 
because of the nature of the school-based examination. 
Third, serum betatrophin levels were determined only 
via EIAAB ELISA, measuring antibodies of N-terminus, 
without verification by another ELISA of C-terminus 
and western blotting. However, the present study also 
had several strengths, including the prospective study 
design and the accurate method used to measure study 
variables. Furthermore, research with children is often 
not affected by certain lifestyle factors, such as alcohol 
consumption and smoking, and may provide information 
about the early initiating stages of the development of 
metabolic disorders induced by risk factors.
Conclusions
This prospective study, for the first time, showed that 
baseline ANGPTL8 concentrations were associated with 
baseline and future changes of TG levels in Korean boys 
and girls after a 3  year follow-up after adjustment for 
confounding factors. Future studies are needed to con-
firm our results in a larger population for a longer period 
and in other ethnic groups.
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